Use and Return of Investigational Sample Clauses

Use and Return of Investigational. Product and Equipment 1.6 P oužití a vrácení Hodnoceného léčiva a Materiálů Sponsor or a duly authorized agent of Sponsor, shall supply Site free of charge with sufficient amount of Investigational Product as described in the Protocol. Investigational Product will be stored, Zadavatel, či jeho řádně oprávněný zástupce, dodá bezplatně Místu provádění klinického hodnocení dostatečné množství Hodnoceného léčiva dle podmínek popsaných v Protokolu. Hodnocené léčivo accounted for and administered in accordance with the Protocol. bude ukládáno, vykazováno a podáváno v souladu s Protokolem. The Site shall use the Study Material provided in connection with the Study, solely for the purpose of properly completing the Study and shall maintain the Study Material as specified by Sponsor and according to applicable laws and regulations, including storage in a locked, secured area at all times. Místo provádění klinického hodnocení bude používat Studijní materiál poskytnutý v souvislosti se Studií výhradně pro účely řádného dokončení Studie a bude jej uchovávat dle pokynů Zadavatele a v souladu s příslušnými právními předpisy, nařízeními a pravidly, včetně povinnosti skladovat Hodnocené léčivo v uzamčeném a zabezpečeném prostoru, a to po celou předmětnou dobu. Upon completion or termination of the Study, the Site shall return or destroy, at Sponsor’s option, Study Material and all Confidential Information (as defined below) at Sponsor’s sole expense. V návaznosti na dokončení či ukončení Studie, Místo provádění klinického hodnocení vrátí či zlikviduje, a to plně dle volby Zadavatele, Studijní materiál i veškeré Důvěrné informace (ve smyslu níže uvedené definice) plně a výlučně na náklady Zadavatele. Institution and Investigator shall comply with all laws and regulations governing the disposition of Investigational Product and any instructions from IQVIA that are not inconsistent with such laws and regulations. Zdravotnické zařízení a Zkoušející se zavazují, že budou jednat v souladu s veškerými právními předpisy, nařízeními a pravidly upravujícími nakládání s Hodnoceným léčivem a jakýmikoli instrukcemi a pokyny poskytnutými IQVIA, jež nejsou v rozporu s takovými právními přepisy, nařízeními a pravidly. The Institution, through the Investigator shall return any equipment provided by Sponsor for use in the Study unless Sponsor and Institution have a written agreement for Institution to acquire the equipment. If there are Site facility improvements provided by IQVIA or Spons...
Sample 1
AutoNDA by SimpleDocs
Use and Return of Investigational. Product and Equipment 1.
Sample 1
Use and Return of Investigational. Product and Equipment 1.6. Použitie a vrátenie skúšaného produktu a vybavenia Sponsor or a duly authorized agent of Sponsor, shall supply Investigator at Institution’s facilities with sufficient amount of Investigational Product as described in the Protocol. Zadávateľ alebo jeho riadne splnomocnený zástupca dodá skúšajúcemu do priestorov zdravotníckeho zariadenia dostatočné množstvo skúšaného produktu, v súlade s protokolom. Institution will enable Investigator to maintain the Investigational Product as specified by Sponsor or IQVIA and according to Applicable Law, including storage in a locked, secured area at all times. Zdravotnícke zariadenie zabezpečí, aby skúšajúci za každých okolností skladoval skúšaný produkt podľa pokynov zadávateľa, resp. spoločnosti IQVIA, a podľa platných právnych predpisov, vrátane skladovania v uzamknutých a zabezpečených priestoroch. Based on assessment of Site’s facilities and needs in connection with the conduct of the Study, Sponsor may provide to Site certain electronic and other equipment as necessary (the “Equipment”) solely for use in performance of the Study. Such Equipment may be leased by Sponsor and provided to Site through a third party (“Lessor”) on behalf of Sponsor or provided directly by Sponsor to Site. Equipment shall be returned to Lessor or Sponsor, as applicable, at the expense of Sponsor, upon the Na základe posúdenia priestorov pracoviska skúšania a potrieb súvisiacich s vykonávaním skúšania môže zadávateľ podľa potreby poskytnúť pracovisku skúšania určité elektronické a iné vybavenie (ďalej „vybavenie“) výhradne na účely vykonávania skúšania. Takéto vybavenie si môže zadávateľ prenajať a poskytnúť ho pracovisku skúšania prostredníctvom tretej strany (ďalej „prenajímateľ“) v mene zadávateľa alebo ho môže zadávateľ priamo poskytnúť pracovisku skúšania. VXA34987 CTA Template Slovakia INST 6Dec2016- based on IQVIA Global template – 15 April 2013 PI: Xxxxx Xxxxx, MD VXA34987 CTA Template Slovakia INST 6Dec2016- based on IQVIA Global template – 15 April 2013 completion or termination of the Study or upon Sponsor’s request, or shall otherwise be disposed of pursuant to the written direction of Lessor or Sponsor as applicable. Site shall implement reasonable and appropriate administrative, physical and technical safeguards to protect the Equipment, shall at all times while the Equipment is in its possession and shall promptly notify Sponsor or its designee (IQVIA) of any malfunctioning Equipment. IQVIA shall e...
Sample 1
Use and Return of Investigational. P oužití a vrácení Hodnoceného léčiva Sponsor shall supply, directly or indirectly, Institution or Investigator with sufficient amount of Investigational Product as described in the Protocol. Site shall use the Investigational Product and all other Materials solely for the purpose of properly conducting and completing the Study, and in accordance with this Agreement, the Protocol and other written instructions provided by or on behalf of Sponsor. Site shall maintain the Investigational Product and all other Materials as specified by Sponsor and according to Applicable Laws and regulations, including storage at all times in a locked, secured area, access to which is limited, to prevent theft or Zadavatel zajistí, přímo nebo či nepřímo, že Zdravotnické zařízení a Zkoušející budou mít k dispozici dostatečné množství Hodnoceného léčiva, jak je popsáno v Protokolu. Místo provádění klinického hodnocení bude používat Hodnocené léčivo a jakýkoli komparační produkt poskytnutý v souvislosti se Studií výhradně pro účely řádného dokončení Studie a bude uchovávat Hodnocené léčivo dle pokynů Zadavatele a v souladu s příslušnými právními předpisy, nařízeními a pravidly. Místo provádění klinického hodnocení bude uchovávat Hodnocené léčivo a další Materiály dle pokynů Zadavatele a v souladu s Příslušnými právními předpisy, včetně povinnosti skladovat Hodnocené léčivo v uzamčeném a zabezpečeném prostoru, ke
Sample 1
Use and Return of Investigational. Zadavatel se zavazuje neprodleně informovat Zdravotnické zařízení o ukončení Studie (předčasném nebo v řádném předpokládaném termínu). Dále je Zadavatel povinen Zdravotnické zařízení neprodleně informovat, v případě, že SUKL pozastaví nebo zakáže provádění Studie a dále bude-li souhlas EK (dočasně nebo trvale) odvolán.
Sample 1
Use and Return of Investigational. Zadavatel se zavazuje neprodleně informovat Instituci o ukončení Klinického hodnocení (předčasném nebo v řádném předpokládaném termínu). Dále je Zadavatel povinen Instituci neprodleně informovat, v případě, že SUKL pozastaví nebo zakáže provádění Klinického hodnocení a dále bude-li souhlas EK (dočasně nebo trvale) odvolán. Zadavatel je rovněž povinen neprodleně informovat Instituci o veškerých skutečnostech, které mohou nepříznivě ovlivnit bezpečnost nebo zdraví Subjektů klinického hodnocení nebo mít vliv na další provádění Klinického hodnocení, včetně informací vzešlých z Klinického hodnocení prováděné na jiných místech hodnocení a informovat Instituci o všech jemu oznámených podezřeních na nežádoucí účinky Hodnoceného přípravku.
Sample 1

Related to Use and Return of Investigational

  • Facilitation of Investigation In case of any allegation of violation of any provisions of this Pact or payment of commission, the BUYER or its agencies shall be entitled to examine all the documents including the Books of Accounts of the BIDDER and the BIDDER shall provide necessary information and documents in English and shall extend all possible help for the purpose of such examination.

  • Corporate Examinations and Investigations Prior to the Closing Date, the parties acknowledge that they have been entitled, through their employees and representatives, to make such investigation of the assets, properties, business and operations, books, records and financial condition of the other as they each may reasonably require. No investigations, by a party hereto shall, however, diminish or waive any of the representations, warranties, covenants or agreements of the party under this Agreement.

  • Survival Regardless of Investigation The indemnification and contribution provided for herein will remain in full force and effect regardless of any investigation made by or on behalf of Indemnitee or any officer, director, employee, agent or controlling person of Indemnitee.

  • Cooperation with Investigations You agree to cooperate with us in the investigation of unusual transactions, poor quality transmissions, and resolution of customer claims, including by providing, upon request and without further cost, any originals or copies of items deposited through the Service in your possession and your records relating to such items and transmissions.

  • No Duty of Investigation Notice in Trust Instruments, etc. No purchaser, lender, transfer agent or other person dealing with the Trustees or with any officer, employee or agent of the Trust shall be bound to make any inquiry concerning the validity of any transaction purporting to be made by the Trustees or by said officer, employee or agent or be liable for the application of money or property paid, loaned, or delivered to or on the order of the Trustees or of said officer, employee or agent. Every obligation, contract, undertaking, instrument, certificate, Share, other security of the Trust, and every other act or thing whatsoever executed in connection with the Trust shall be conclusively taken to have been executed or done by the executors thereof only in their capacity as Trustees under this Declaration or in their capacity as officers, employees or agents of the Trust. The Trustees may maintain insurance for the protection of the Trust Property, its Shareholders, Trustees, officers, employees and agents in such amount as the Trustees shall deem adequate to cover possible tort liability, and such other insurance as the Trustees in their sole judgment shall deem advisable or is required by the 1940 Act.

  • Grievance Investigations Where an employee has asked or is obliged to be represented by the Institute in relation to the presentation of a grievance and an employee acting on behalf of the Institute wishes to discuss the grievance with that employee, the employee and the representative of the employee will, where operational requirements permit, be given reasonable leave with pay for this purpose when the discussion takes place in the headquarters area of such employee and leave without pay when it takes place outside the headquarters area of such employee.

  • Litigation Cooperation From the date hereof and continuing through the termination of this Agreement, make available to Bank, without expense to Bank, Borrower and its officers, employees and agents and Borrower’s books and records, to the extent that Bank may deem them reasonably necessary to prosecute or defend any third-party suit or proceeding instituted by or against Bank with respect to any Collateral or relating to Borrower.

  • Tax Examinations Abroad 1. A Contracting Party may allow representatives of the competent authority of the other Contracting Party to enter the territory of the first-mentioned Party to interview individuals and examine records with the written consent of the persons concerned. The competent authority of the second-mentioned Party shall notify the competent authority of the first-mentioned Party of the time and place of the meeting with the individuals concerned. 2. At the request of the competent authority of one Contracting Party, the competent authority of the other Contracting Party may allow representatives of the competent authority of the first-mentioned Party to be present at the appropriate part of a tax examination in the second-mentioned Party. 3. If the request referred to in paragraph 2 is acceded to, the competent authority of the Contracting Party conducting the examination shall, as soon as possible, notify the competent authority of the other Party about the time and place of the examination, the authority or official designated to carry out the examination and the procedures and conditions required by the first-mentioned Party for the conduct of the examination. All decisions with respect to the conduct of the tax examination shall be made by the Party conducting the examination.

  • Litigation and Regulatory Cooperation During and after the Executive’s employment, the Executive shall cooperate fully with the Company in the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed by the Company. The Executive’s full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after the Executive’s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable out-of-pocket expenses incurred in connection with the Executive’s performance of obligations pursuant to this Section 7(f).

  • Examination of Implementation 1. Without prejudice to the procedures set out in Article 188 (Compensation), once the period of time set out in paragraph 3 of Article 186 (Implementation of the Report) has expired, and there is disagreement between the disputing Parties as to the existence or consistency of the measures taken to comply with the Panel report, such dispute shall be referred to the original Panel wherever possible. If not possible, the procedure pursuant to Article 179 (Panel Selection) shall be followed to appoint a new Panel, in which event the periods set out thereof shall be reduced by half (22). 2. This Panel shall issue its report on the matter within 60 days after the date of the referral of the matter to it. When the Panel considers that it cannot provide its report within this timeframe, it shall inform the Parties in writing of the reasons for the delay together with an estimate of the period within which it will submit its report. Any delay shall not exceed a further period of 30 days unless the Parties otherwise agree.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!